Skip to main content

Milligan Sandra

No open-market purchases or sales filed in the past year.

Current role at each company

  • GOSSGossamer Bio, Inc.Directoras of Sep 25, 2026
  • SYRESpyre Therapeutics, Inc.Directoras of May 29, 2026
  • AWHLAspira Women's Health Inc.Interim CEOas of Jan 29, 2025
  • OGNOrganon & Co.Head of Research & Developmentas of May 8, 2023

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
–
0 filings
Net
–
Bought minus sold
Companies
0
With open-market trades

Trades

Every Form 4 that lists Milligan Sandra as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

GOSS Gossamer Bio, Inc.

Director2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 20, 2025 (view filing)Aug 191 dayMilligan SandraDirectorPPurchase+26.1K$1.92+$50.0K+81.4%58.0K after
Nov 17, 2023 (view filing)Nov 152 daysMilligan SandraDirectorPPurchase+32.0K$0.79+$25.3KNew position32.0K after